JNBA Financial Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-400
Closed -$46.3K 761
2023
Q3
$46.3K Hold
400
0.01% 284
2023
Q2
$41.1K Hold
400
﹤0.01% 307
2023
Q1
$43.7K Hold
400
0.01% 298
2022
Q4
$45.5K Hold
400
0.01% 287
2022
Q3
$25K Hold
400
﹤0.01% 351
2022
Q2
$32K Hold
400
﹤0.01% 333
2022
Q1
$42K Hold
400
0.01% 312
2021
Q4
$43K Hold
400
0.01% 326
2021
Q3
$44K Hold
400
0.01% 309
2021
Q2
$37K Hold
400
0.01% 326
2021
Q1
$37K Hold
400
0.01% 319
2020
Q4
$29K Hold
400
﹤0.01% 322
2020
Q3
$31K Hold
400
0.01% 292
2020
Q2
$22K Hold
400
﹤0.01% 325
2020
Q1
$12K Hold
400
﹤0.01% 367
2019
Q4
$14K Hold
400
﹤0.01% 397
2019
Q3
$11K Hold
400
﹤0.01% 402
2019
Q2
$10K Buy
+400
New +$10.1K ﹤0.01% 440

Other funds holding HZNP

JNBA Financial Advisors's HZNP Position: Q4 2023 in Review

JNBA Financial Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 400 shares — an estimated $46.3K sold.

JNBA Financial Advisors first reported a position in HZNP in Q2 2019 and held it in 18 quarters. The position peaked at $46.3K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • JNBA Financial Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • JNBA Financial Advisors sold 400 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $46.3K.
  • JNBA Financial Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 18 quarters.
  • JNBA Financial Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $46.3K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on JNBA Financial Advisors's 13F filing for Q4 2023, filed 8 Feb 2024.